TBX10, a member of the Tbx1-subfamily of conserved developmental genes, is located at human chromosome 11q13 and proximal mouse chromosome 19
Law, D J, Garvey, N, Agulnik, S I, Perlroth, V, Hahn, O M, Rhinehart, R E, Gebuhr, T C, Silver, L M
Published in Mammalian genome (01.05.1998)
Published in Mammalian genome (01.05.1998)
Get full text
Journal Article
Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer
Sikov, W. M., Perou, C. M., Golshan, M., Collyar, D., Berry, D. A., Hahn, O. M., Singh, B., Hudis, C., Winer, E. P.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article
A phase II trial of gemcitabine(G), capecitabine (C), and bevacizumab (B) in patients (pts) with metastatic renal cell carcinoma (RCC)
Chung, E. K., Posadas, E. M., Kasza, K., Karrison, T., Manchen, E., Michalak, L., Hahn, O. M., Stadler, W. M.
Published in Journal of clinical oncology (20.05.2009)
Published in Journal of clinical oncology (20.05.2009)
Get full text
Journal Article
Dyamic contrast enhanced MRI (DCE-MRI) pharmacodynamic (PD) study of sorafenib in metastatic renal cell carcinoma (RCC): Results of a randomized, phase II trial
hahn, O. M., Yeng, C., Medved, M., Karczmar, G., Kistner, E., Manchen, B., Mitchell, M., Karrison, T., Ratain, M., Stadler, W. M.
Published in Journal of clinical oncology (20.06.2007)
Published in Journal of clinical oncology (20.06.2007)
Get full text
Journal Article
Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)
Sikov, WM, Berry, DA, Perou, CM, Singh, B, Cirrincione, CT, Tolaney, SM, Somlo, G, Port, ER, Qamar, R, Sturtz, K, Mamounas, E, Golshan, M, Bellon, JR, Collyar, D, Hahn, OM, Carey, LA, Hudis, CA, Winer, EP
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Get full text
Journal Article
Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)
Sikov, WM, Berry, DA, Perou, CM, Singh, B, Cirrincione, C, Tolaney, S, Kuzma, CS, Pluard, TJ, Somlo, G, Port, E, Golshan, M, Bellon, JR, Collyar, D, Hahn, OM, Carey, LA, Hudis, C, Winer, EP
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Get full text
Journal Article
A phase II trial of a mammalian target of rapamycin inhibitor, temsirolimus, in patients with metastatic breast cancer
Hahn, OM, Ma, CX, Lin, L, Hou, D, Sattar, H, Olopade, FO, Nanda, R, Hoffman, PC, Naughton, MJ, Pluard, T, Watson, MA, Ellis, M, Conzen, SD, Fleming, GF
Published in Cancer research (Chicago, Ill.) (15.01.2009)
Published in Cancer research (Chicago, Ill.) (15.01.2009)
Get full text
Journal Article